drugset
drugset / Trial / NCT03641573

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

NCT03641573 ↗

Phase 1 Completed 8 enrolled Asana BioSciences
NaSingle-groupOpen-labelOther

Summary

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\] ASN002 Following a Single Oral Dose in Healthy Male Subjects

Timeline

Start
2018-10-11
Primary completion
2018-10-21
Completion
2018-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Gusacitinib Small molecule 60 mg Oral

Indications

No indication recorded.